{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:52:39Z","timestamp":1794185559931,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019531","name":"Apellis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ajo.2025.04.016","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T11:53:38Z","timestamp":1745409218000},"page":"350-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE"],"prefix":"10.1016","volume":"276","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0179-1006","authenticated-orcid":false,"given":"Allen","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-1614","authenticated-orcid":false,"given":"David","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilsher S.","family":"Dhoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-1165","authenticated-orcid":false,"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-2160","authenticated-orcid":false,"given":"Jordi","family":"Mones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Heier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8719-6709","authenticated-orcid":false,"given":"Ashkan M.","family":"Abbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J.","family":"Singerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejla","family":"Vajzovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhi","family":"Vilupuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Baumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajo.2025.04.016_bib0001","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/IAE.0000000000001392","article-title":"The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target","volume":"37","author":"Boyer","year":"2017","journal-title":"Retina"},{"issue":"17","key":"10.1016\/j.ajo.2025.04.016_bib0002","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1080\/14656566.2023.2257604","article-title":"The complement system: a novel therapeutic target for age-related macular degeneration","volume":"24","author":"Shughoury","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ajo.2025.04.016_bib0003","unstructured":"Syfovre [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc.; 2024."},{"issue":"11","key":"10.1016\/j.ajo.2025.04.016_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103757","article-title":"Therapeutic targeting of the complement system in ocular disease","volume":"28","author":"Rathi","year":"2023","journal-title":"Drug Discov Today"},{"issue":"5\u2013a Suppl","key":"10.1016\/j.ajo.2025.04.016_bib0005","first-page":"S2","article-title":"Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system","volume":"29","author":"Bakri","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"10.1016\/j.ajo.2025.04.016_bib0006","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/13543784.2023.2276759","article-title":"Investigational drugs inhibiting complement for the treatment of geographic atrophy","volume":"32","author":"Ferro Desideri","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"10.1016\/j.ajo.2025.04.016_bib0007","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","article-title":"Pegcetacoplan: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"issue":"10411","key":"10.1016\/j.ajo.2025.04.016_bib0008","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"issue":"10411","key":"10.1016\/j.ajo.2025.04.016_bib0009","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2025.04.016_bib0010","doi-asserted-by":"crossref","DOI":"10.3928\/23258160-20250217-01","article-title":"Pegcetacoplan for geographic atrophy over 30 months: data from OAKS, DERBY, and the GALE long-term extension study","author":"Goldberg","year":"2025","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"10.1016\/j.ajo.2025.04.016_bib0011","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ophtha.2015.09.036","article-title":"Natural history of geographic atrophy progression secondary to age-related macular degeneration (Geographic Atrophy Progression Study)","volume":"123","author":"Schmitz-Valckenberg","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.016_bib0012","unstructured":"Study to evaluate the safety of intravitreal APL-2 in patients diagnosed with geographic atrophy [NCT03777332]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03777332. Accessed May 13, 2025."},{"issue":"6","key":"10.1016\/j.ajo.2025.04.016_bib0013","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/09286580591005723","article-title":"Modelling the natural history of geographic atrophy in patients with age-related macular degeneration","volume":"12","author":"Dreyhaupt","year":"2005","journal-title":"Ophthalmic Epidemiol"},{"issue":"2","key":"10.1016\/j.ajo.2025.04.016_bib0014","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ophtha.2006.09.016","article-title":"The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials","volume":"114","author":"Sunness","year":"2007","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2025.04.016_bib0015","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/IAE.0000000000000504","article-title":"MP1 and MAIA fundus perimetry in healthy subjects and patients affected by retinal dystrophies","volume":"35","author":"Parodi","year":"2015","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.ajo.2025.04.016_bib0016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1167\/tvst.9.7.19","article-title":"Interpreting MAIA microperimetry using age- and retinal loci-specific reference thresholds","volume":"9","author":"Charng","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ajo.2025.04.016_bib0017","unstructured":"Steinle N., Heier J., Singh R.P., et al. A phase 1b multi-center, open label, single-arm safety study of intravitreal pegcetacoplan supporting the phase 3 DERBY and OAKS studies for geographic atrophy [poster]. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; May 1-7, 2021; virtual event."},{"key":"10.1016\/j.ajo.2025.04.016_bib0018","unstructured":"Goldberg R.A., Kitchens J.W., Lad E., Zarbin M.A. The evolving treatment paradigm in geographic atrophy. Retina Today. 2024;(May-June suppl):1\u20138. Available at: https:\/\/retinatoday.com\/articles\/2024-may-june-supplement2\/the-evolving-treatment-paradigm-in-geographic-atrophy. Accessed May 13, 2025."},{"issue":"3","key":"10.1016\/j.ajo.2025.04.016_bib0019","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.016_bib0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","article-title":"Complement and its receptors: new insights into human disease","volume":"32","author":"Holers","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"10.1016\/j.ajo.2025.04.016_bib0021","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.oret.2022.05.030","article-title":"The effect of pegcetacoplan treatment on photoreceptor maintenance in geographic atrophy monitored by artificial intelligence-based OCT analysis","volume":"6","author":"Riedl","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.016_bib0022","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.oret.2022.08.003","article-title":"Predicting topographic disease progression and treatment response of pegcetacoplan in geographic atrophy quantified by deep learning","volume":"7","author":"Vogl","year":"2023","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"10.1016\/j.ajo.2025.04.016_bib0023","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jamaophthalmol.2024.1269","article-title":"Pegcetacoplan treatment and consensus features of geographic atrophy over 24 months","volume":"142","author":"Fu","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.04.016_bib0024","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ophtha.2024.08.017","article-title":"Disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT","volume":"132","author":"Schmidt-Erfurth","year":"2025","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2025.04.016_bib0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaophthalmol.2021.6067","article-title":"Association of pegcetacoplan with progression of incomplete retinal pigment epithelium and outer retinal atrophy in age-related macular degeneration: a post hoc analysis of the FILLY randomized clinical trial","volume":"140","author":"Nittala","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.016_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22404-9","article-title":"Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy","volume":"12","author":"Pfau","year":"2022","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.ajo.2025.04.016_bib0027","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.oret.2020.11.003","article-title":"Relationship of topographic distribution of geographic atrophy to visual acuity in nonexudative age-related macular degeneration","volume":"5","author":"Shen","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"10.1016\/j.ajo.2025.04.016_bib0028","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/2474126419859454","article-title":"Percentage of foveal vs total macular geographic atrophy as a predictor of visual acuity in age-related macular degeneration","volume":"3","author":"Bagheri","year":"2019","journal-title":"J Vitreoretin Dis"},{"issue":"7","key":"10.1016\/j.ajo.2025.04.016_bib0029","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamaophthalmol.2021.1407","article-title":"Enlargement of geographic atrophy from first diagnosis to end of life","volume":"139","author":"Colijn","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.04.016_bib0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2025.04.016_bib0031","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.oret.2020.01.019","article-title":"Visual function decline resulting from geographic atrophy: results from the Chroma and Spectri phase 3 trials","volume":"4","author":"Heier","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.016_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100351","article-title":"Macular sensitivity endpoints in geographic atrophy: exploratory analysis of Chroma and Spectri clinical trials","volume":"4","author":"Chang","year":"2023","journal-title":"Ophthalmol Sci"},{"issue":"3","key":"10.1016\/j.ajo.2025.04.016_bib0033","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/ICU.0000000000000153","article-title":"Introduction to microperimetry and its use in analysis of geographic atrophy in age-related macular degeneration","volume":"26","author":"Hanout","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ajo.2025.04.016_bib0034","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40942-020-00217-0","article-title":"Test-retest variability of microperimetry in geographic atrophy","volume":"6","author":"Alibhai","year":"2020","journal-title":"Int J Retina Vitreous"},{"issue":"3","key":"10.1016\/j.ajo.2025.04.016_bib0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.survophthal.2019.01.014","article-title":"Microperimetry for geographic atrophy secondary to age-related macular degeneration","volume":"64","author":"Csaky","year":"2019","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.04.016_bib0036","first-page":"536","volume":"108","author":"Fu","year":"2024","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.016_bib0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40942-021-00358-w","article-title":"Analysis of urgent follow up visits and complications after intravitreal injections: a retrospective cohort study","volume":"8","author":"Miller","year":"2022","journal-title":"Int J Retina Vitreous"},{"issue":"4","key":"10.1016\/j.ajo.2025.04.016_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100318","article-title":"Progression of geographic atrophy: retrospective analysis of patients from the IRIS\u00ae registry (Intelligent Research in Sight)","volume":"3","author":"Rahimy","year":"2023","journal-title":"Ophthalmol Sci"},{"issue":"4","key":"10.1016\/j.ajo.2025.04.016_bib0039","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000443209","article-title":"Geographic atrophy and choroidal neovascularization in the same eye: a review","volume":"55","author":"Kaszubski","year":"2016","journal-title":"Ophthalmic Res"},{"issue":"17","key":"10.1016\/j.ajo.2025.04.016_bib0040","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial","volume":"37","author":"Patel","year":"2023","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.016_bib0041","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13104-023-06531-8","article-title":"Piloting a forced-choice task to elicit treatment preferences in geographic atrophy","volume":"16","author":"Enoch","year":"2023","journal-title":"BMC Res Notes"},{"issue":"17","key":"10.1016\/j.ajo.2025.04.016_bib0042","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1038\/s41433-023-02571-3","article-title":"Exploring patient acceptability of emerging intravitreal therapies for geographic atrophy: a mixed-methods study","volume":"37","author":"Enoch","year":"2023","journal-title":"Eye (Lond)"},{"issue":"22","key":"10.1016\/j.ajo.2025.04.016_bib0043","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2015.10.014","article-title":"Making sense of statistics in clinical trial reports: part 1 of a 4-part series on statistics for clinical trials","volume":"66","author":"Pocock","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ajo.2025.04.016_bib0044","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/24741264231220224","article-title":"Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS Research and Safety in Therapeutics (ReST) Committee","volume":"8","author":"Witkin","year":"2024","journal-title":"J Vitreoretin Dis"},{"issue":"2","key":"10.1016\/j.ajo.2025.04.016_bib0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/24741264241228648","article-title":"Occlusive retinal vasculitis after a single injection of pegcetacoplan","volume":"8","author":"Abi Karam","year":"2024","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.ajo.2025.04.016_bib0046","article-title":"Retinal vasculitis following intravitreal pegcetacoplan administration","volume":"33","author":"Douros","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.ajo.2025.04.016_bib0047","unstructured":"Second quarter 2024 financial results Conference Call [presentation]. Apellis. 2024. Available at: https:\/\/investors.apellis.com\/static-files\/bcbe4eff-ecb5-4029-a924-e8ddcebb468a. Accessed May 13, 2025."},{"issue":"6","key":"10.1016\/j.ajo.2025.04.016_bib0048","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and Spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500193X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500193X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T08:56:51Z","timestamp":1751965011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942500193X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":48,"alternative-id":["S000293942500193X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.04.016","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}